AIDS Research and Treatment / 2012 / Article / Tab 1

Clinical Study

Oral HIV-Associated Kaposi Sarcoma: A Clinical Study from the Ga-Rankuwa Area, South Africa

Table 1

Clinical and laboratory features of the patients at the time of oral HIV-KS diagnosis.

MalesFemalesTotal

Number of patients (%)17 (46%)20 (54%)37 (100%)
 Age (years)
  Mean343333.4
  Range 11–5519–4611–55
  Standard deviation 12.537.6910.08
Tobacco usage (%)7 (41%)2 (10%)9 (24%)
Number of patients in whom the initial presentation of HIV-KS was in the mouth8 (47%)13 (65%)21 (57%)
Number of patients in whom the initial presentation of HIV-KS was concurrently in the mouth and skin3 (18%)3 (15%)6 (16%)
Number of patients who developed cutaneous HIV-KS before oral HIV-KS diagnosis6 (35%)4 (20%)10 (27%)
Other oral lesions present
 Pseudomembranous candidiasis7 (41%)5 (25%)12 (34%)
 Hairy leukoplakia1 (5%)1 (2%)
 Necrotizing gingivitis1 (6%)1 (2%)

Total number of patients8 (47%)6 (30%)14 (38%)

Average CD4+ T-cell count at KS diagnosis (data available for 33 patients) [cells/mm3]14185107
 Range12–409 13–26112–409
 Standard deviation117.4077.99106.99
Number of patients diagnosed with HIV infection and oral KS at the same time10 (59%)7 (35%)17 (46%)
Number of patients who were diagnosed with HIV infection before the diagnosis of oral KS7 (41%)13 (65%)20 (54%)
Number of patients with single oral HIV-KS lesions5 (29%)3 (15%)8 (22%)
Number of patients with multiple oral HIV-KS lesions12 (71%)17 (85%)29 (78%)
Lesion phenotype
 Number of macular lesions 9 (20%)8 (17%)17 (18%)
 Number of papular lesions10 (22%)11 (23%)21 (23%)
 Number of nodular lesions16 (36%)17 (35%)33 (35%)
 Number of exophytic lesions10 (22%)12 (25%)22 (24%)

Total number of lesions45 (100%)48 (100%)93 (100%)

Lesion size
 Number of lesions <10 mm15 (33%)5 (10%)20 (22%)
 Number of lesions ≥10 mm ≤50 mm25 (56%)40 (83%)65 (70%)
 Number of lesions >50 mm5 (11%)3 (7%)8 (8%)

Total number of lesions45 (100%)48 (100%)93 (100%)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.